Wednesday, July 30, 2025 HDC1 sub-study: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on SWOG S1826Rutherford SC, Li H, Herrera AF, LeBlanc M, Ahmed S, Davison K, Parsons SK, Unger JM, Perry AM, Casulo C, Bartlett NL, Tuscano JM, Hess BT, Torka P, Kumar P, Jacobs R, Song JY, Castellino SM, Kahl B, Leonard JP, Smith SM, Friedberg JW, Evens AM. Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 (ONLINE). Journal of Clinical Oncology 2025.https://ascopubs.org/doi/abs/10.1200/JCO-25-00204 Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. Researchers report on a subset analysis of older patients (60 years and older) enrolled in the phase three (CCTG HDC1) S1826 trial conducted by SWOG that randomly assigned patients with newly diagnosed advanced-stage (III-IV) cHL to six cycles of nivolumab (N)–AVD or brentuximab vedotin (BV)–AVD.
